Biosign Receives Reimbursement Approval from NexgenRx

Toronto, March 17, 2010 (ots/PRNewswire) - Biosign Technologies Inc.
(CNSX: BIO) (the "Company" or "Biosign") today announced it has
received notification that NexgenRx will include Biosign's UFIT(R)
device and services into their Benefits Plans for reimbursement
according to regulatory clearances in the relevant jurisdiction.

Ronald C. Louks, President & CEO of NexgenRx, said: "We see
diabetic plan members and their dependents migrating to this
technology very quickly as they lessen their dependency on the
current invasive monitoring devices. That alone is reason enough.
However, when you factor in the fractionally lower cost associated
with the Biosign monthly monitoring charges, compared to the cost of
the consumable strips that plan sponsors are reimbursing through
health plans, this becomes even more compelling."

UFIT is Biosign's system for online delivery of health monitoring
services to individuals. All services, including blood pressure and
blood glucose testing, rely on digital representations of the pulse
taken at the wrist through an inflatable cuff by a portable device
connected to a computer. The noninvasive, multifunctional monitor
brings an unprecedented blend of convenience and performance to
self-testing in terms of quality, access, and cost.

John Anders SVP, Business Development at Biosign, stated: "The
market strength of NexgenRx is derived from combining industry
leading technology and clinical expertise to deliver better medical
outcomes at lower costs. We are very pleased to see that NexgenRx is
supportive of our offering as it fits perfectly into their customer
value proposition."

About Biosign Technologies Inc.

Biosign provides biomedical systems. Key applications include
intelligent systems for noninvasive monitoring of common health risks
associated with blood pressure, glucose, medication. The core
technology combines measurement, analysis, and rapid knowledge
formation to support health monitoring across global markets. The
UFIT(R) medical device technology powers quality data collection and
analytics for clinical diagnostics, self-care, wellness, disease
state evaluation & management, and remote patient monitoring. For
more information on Biosign please visit http://www.biosign.com.

About NexgenRx

NexgenRx is a growing health benefits management company engaged
in the design, management and administration of health benefit plans
offered by employers and other plan sponsors for the benefit of
their employees and plan members. More information on NexgenRx can
be found at http://www.nexgenrx.com.

The CNSX has neither approved nor disapproved the contents of
this press release.

For further information: Radu Leca, President & CEO, Biosign
Technologies Inc., Phone: +1(416)218-9800 ext. 234, Email:
[email protected].

Rückfragehinweis:
CONTACT: For further information: Radu Leca, President & CEO,
BiosignTechnologies Inc., Phone: +1(416)218-9800 ext. 234, Email:
[email protected].

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | PRN

print